Sight Sciences (SGHT) Common Equity (2020 - 2026)

Sight Sciences has reported Common Equity for 7 years, with the latest figure at $53.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 30.56% year-over-year to $53.9 million; the trailing twelve-month figure through Mar 2026 stood at $53.9 million (down 30.56% YoY), and the FY2025 full-year result was $63.9 million, down 26.94% from the prior year.
• Common Equity for Q1 2026 stood at $53.9 million, down from $63.9 million in the prior quarter.
• The five-year high for Common Equity was $211.9 million in Q1 2022, with the low at $53.9 million in Q1 2026.
• Average Common Equity over 5 years is $117.0 million, with a median of $109.2 million recorded in 2024.
• Year-over-year, Common Equity surged 310.23% in 2022 and tumbled 32.3% in 2025.
• Tracing SGHT's Common Equity over 5 years: stood at $160.1 million in 2022, then fell by 24.9% to $120.2 million in 2023, then fell by 27.19% to $87.5 million in 2024, then decreased by 26.94% to $63.9 million in 2025, then retreated by 15.7% to $53.9 million in 2026.
• The last three Common Equity figures came in at $53.9 million (Q1 2026), $63.9 million (Q4 2025), and $64.3 million (Q3 2025), per Business Quant data.

Peer Comparison